Solstice Advanced Materials Inc. Common Stock
SOLS
$60.23
-0.22%
Solstice Advanced Materials Inc. is a diversified specialty chemicals company that was spun off from Honeywell in late 2025, producing low global warming potential refrigerants for HVAC and automotive applications, materials for building and construction, semiconductor production, healthcare packaging, and defense, and operating the only active uranium conversion business in the United States. As a newly independent pure-play, Solstice holds a distinctive competitive identity anchored in regulatory tailwinds — its low-GWP refrigerant portfolio is positioned to benefit from global hydrofluorocarbon phasedowns, while its uranium conversion asset is a genuinely scarce strategic monopoly within the domestic supply chain. The current investor narrative is dominated by the post-spinoff transition: the stock surged to a 52-week high of $90.80 before suffering a sharp July 2026 drawdown that erased roughly 37% from peak levels, with the market debating whether the selloff reflects genuine operational deterioration or an overreaction to spinoff-related noise and index rebalancing flows. Recent news flow has centered on the broader Honeywell three-way breakup, with commentary suggesting the automation and aerospace pieces are drawing more investor enthusiasm than the materials spinoff, leaving Solstice to prove its standalone earnings power and capital allocation discipline.…
SOLS
Solstice Advanced Materials Inc. Common Stock
$60.23
Related headlines
Investment Opinion: Should I buy SOLS Today?
Rating: Hold with a bias toward accumulation on weakness. The core thesis is that Solstice is a fundamentally sound specialty chemicals spinoff with a strong buy analyst consensus (1.375 recommendation mean) and an average target price of $79.63 implying 38.0% upside, but the severe relative underperformance (-41.8% versus SPY over six months) and 37.5% drawdown from peak suggest the market is not yet convinced of the standalone earnings story. The risk/reward is attractive for patient investors willing to endure near-term volatility, but the absence of a clear technical bottom and the ongoing post-spinoff transition argue against aggressive buying at current levels.
The supporting evidence is compelling: forward PE of 17.2x on an estimated EPS of $4.70 versus trailing PE of 32.6x implies earnings are expected to roughly double; Q2 2026 revenue grew 11.1% YoY to $1.148 billion with net margin expanding to 10.4% from 1.5% a year ago; EBITDA of $279 million (24.3% margin) was the strongest in eight quarters; and free cash flow of $124 million in Q2 2026 with $750 million in cash provides adequate liquidity. The PS ratio of 1.99x is near the bottom of its historical band (down from 12.3x), and the EV/EBITDA of 10.5x is reasonable for a specialty chemicals business with 32.2% gross margins and an 18.8% operating margin. The 16.8% ROE and 7.6% ROA demonstrate efficient capital deployment despite the moderate leverage.
The biggest risks that could invalidate the thesis are: (1) gross margin continuing to compress below 30%, which would undermine the earnings normalization story; (2) revenue growth decelerating below 8% if HVAC or automotive end markets weaken; and (3) the market permanently re-rating specialty chemicals spinoffs lower, as suggested by the PS collapse from 12.3x to 1.99x. This Hold would upgrade to Buy if the stock establishes a base above $60 and Q3 2026 results confirm margin expansion above 33%, or downgrade to Sell if revenue growth falls below 8% or gross margin drops below 30%. The valuation verdict is fairly valued to slightly undervalued: the forward PE of 17.2x is at the low end of the historical range (16.6x-46.7x), and the PS of 1.99x is near multi-year lows, but the PB of 5.47x remains elevated relative to early 2025 levels.
Sign up to view all
SOLS 12-Month Price Forecast
Solstice presents a classic post-spinoff value debate: the fundamentals are improving (Q2 2026 net income of $119 million, 10.4% net margin, strongest in eight quarters) and analysts are overwhelmingly bullish (strong buy consensus, 38% average upside), yet the stock has been crushed (-37.5% from peak, -41.8% relative to SPY over six months). The forward PE of 17.2x on an estimated $4.70 EPS is undeniably cheap if the estimate is achievable, but the trailing EPS of $0.03 and the 37.5% max drawdown suggest the market has serious doubts about the standalone earnings power. I would upgrade to bullish if Q3 2026 results confirm revenue growth above 11% and operating margin above 19%, and downgrade to bearish if revenue growth falls below 8% or gross margin drops below 30%. The risk/reward is balanced at current levels, favoring patient accumulation over aggressive buying.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Solstice Advanced Materials Inc. Common Stock's 12-month outlook, with a consensus price target around $79.22 and implied upside of +31.5% versus the current price.
Average Target
$79.22
0 analysts
Implied Upside
+31.5%
vs. current price
Analyst Count
—
covering this stock
Price Range
$65 - $86
Analyst target range
Solstice is covered by 8 analysts with a consensus recommendation of "strong_buy" and a recommendation mean of 1.375 (where 1.0 is a strong buy and 5.0 is a strong sell), indicating a strongly bullish consensus. The average target price of $79.63 implies 38.0% upside from the current price of $57.70, a substantial gap that suggests analysts believe the recent selloff is overdone. The target range spans from a low of $65.00 (12.7% upside) to a high of $86.00 (49.0% upside), a relatively tight spread of $21.00 that signals stronger conviction among analysts than is typical for a recently spun-off company. The consensus leans decisively bullish, with the average target sitting 38% above the current price and even the lowest target implying double-digit upside, which is a powerful signal that the market's pessimism may be excessive relative to analyst expectations. The high target of $86.00 assumes successful execution on the standalone strategy, including margin expansion from the current 18.8% operating margin toward the 20%+ level, continued revenue growth above 10%, and multiple expansion as the market gains confidence in the spinoff's earnings power. The low target of $65.00 prices in more modest assumptions — perhaps mid-single-digit revenue growth, stable margins, and a discount multiple reflecting spinoff-related uncertainty and the company's moderate leverage. Institutional ratings data shows a clear pattern of upgrades and reiterations: UBS upgraded from Neutral to Buy on July 13, 2026, and Truist Securities upgraded from Hold to Buy on July 9, 2026, while RBC Capital, BMO Capital, and UBS have all reiterated Outperform or Buy ratings through late July. The only Neutral ratings come from Mizuho, and the absence of any Sell ratings across the coverage universe reinforces the bullish tilt. The estimated revenue average of $5.118 billion for the forward period, against TTM revenue of roughly $4.1 billion, implies analysts expect approximately 25% revenue growth, which is aggressive but supported by the Q2 2026 YoY growth of 11.1% and the potential for acceleration as refrigerant regulations tighten and semiconductor demand recovers.
Drowning in data?
Find the real signal!
Bulls vs Bears: SOLS Investment Factors
The bull case rests on a powerful combination of analyst conviction (strong buy consensus, 38% average upside) and a dramatic forward earnings inflection (forward PE of 17.2x versus trailing 32.6x), supported by the strongest quarterly profitability in eight quarters. The bear case is anchored in severe relative underperformance (-41.8% versus SPY over six months), a 37.5% drawdown from peak, and a PS ratio that has collapsed from 12.3x to 1.99x, suggesting the market has permanently de-rated the stock. Currently, the bear evidence carries more weight because price action and relative strength are the ultimate arbiters of near-term direction, and both are deeply negative despite strong Q2 fundamentals. The single most important tension is whether the July 2026 crash was an overreaction to spinoff-related noise and index rebalancing flows, or the beginning of a structural de-rating driven by concerns about standalone execution and the loss of Honeywell's parental support. If Q3 2026 results confirm the Q2 margin trajectory and revenue growth accelerates above 11%, the bull case would gain decisive evidence; if margins compress or revenue growth stalls, the bear case would be validated.
Bullish
- Analyst consensus strong buy with 38% upside: All 8 covering analysts rate SOLS a strong buy (recommendation mean 1.375), with an average target price of $79.63 implying 38.0% upside from the current $57.70. Even the lowest target of $65.00 implies 12.7% upside, and there are zero sell ratings, indicating broad conviction that the selloff is overdone.
- Forward PE of 17.2x on 4.70 EPS estimate: The forward PE of 17.2x is less than half the trailing PE of 32.6x, reflecting analyst expectations that EPS will surge from a trailing $0.03 to $4.70 as spinoff costs roll off and operating leverage materializes. This compression implies the market is pricing in substantial earnings normalization that has not yet been reflected in the stock price.
- Q2 profitability strongest in eight quarters: Q2 2026 net income of $119 million (10.4% net margin) and EBITDA of $279 million (24.3% margin) represent the best quarterly profitability in the trailing eight quarters, with net margin expanding from 8.6% in Q1 2026 and 1.5% in Q2 2025. Gross margin also improved sequentially to 32.2% from 31.9%.
- Revenue growth accelerating to 11.1% YoY: Q2 2026 revenue of $1.148 billion grew 11.1% year-over-year and rose sequentially from $991 million in Q1 2026 and $987 million in Q4 2025. The upward trajectory from $969 million in Q3 2025 reflects genuine demand tailwinds from low-GWP refrigerant regulations and semiconductor materials.
Bearish
- Severe relative underperformance versus SPY: SOLS has underperformed the S&P 500 by 31.4% over three months and 41.8% over six months, while SPY gained 15.0% over the past year. This persistent relative weakness signals that institutional investors are rotating away from the materials spinoff in favor of the automation and aerospace pieces of the Honeywell breakup.
- 37.5% max drawdown from 52-week high: The stock has fallen 37.5% from its 52-week high of $90.80 to $57.70, trading at only 35.1% of its annual range. The July 2026 crash from $80.19 to $62.10 in just four trading days suggests a structural de-rating rather than a temporary dip, and the stock remains 28.0% below its level three months ago.
- Elevated leverage with 1.72 debt-to-equity: The debt-to-equity ratio of 1.72 and current ratio of 1.39 are moderate but not fortress-like for a specialty chemicals company, and interest expense of $23 million in Q2 2026 consumes a meaningful portion of the $222 million operating income. The $750 million cash position provides some cushion, but the balance sheet lacks the flexibility of larger peers.
- Gross margin compression versus prior year: Q2 2026 gross margin of 32.2% is below the 34.6% recorded in Q2 2025, indicating cost pressure or unfavorable mix shift despite the net margin improvement. The heavy product concentration ($1.062 billion of $1.148 billion revenue) means any HVAC or automotive end-market softness would disproportionately impact results.
SOLS Technical Analysis
Solstice is in a clear intermediate-term downtrend that has overwhelmed its longer-term post-spinoff gains. The stock trades at $57.70, which is only 35.1% of its 52-week range (low of $40.43, high of $90.80), having fallen 28.0% over the past three months and 24.5% over six months, though it remains up 17.1% year-to-date. This positioning — well below the midpoint of the annual range but still positive on a YTD basis — suggests the stock is in a corrective phase within a broader post-IPO uptrend, and the proximity to the lower quartile of the range signals that sellers remain in control rather than a clean value opportunity. Recent momentum is weak but showing tentative stabilization: the 1-month change of -5.4% is a meaningful deceleration from the 3-month decline of -28.0%, implying the pace of selling is moderating. However, the stock's relative strength versus SPY is deeply negative across every window — -6.0% over 1 month, -31.4% over 3 months, and -41.8% over 6 months — confirming severe underperformance against a benchmark that gained 15.0% over the past year. The 1-month trend (-5.4%) conflicts with the YTD trend (+17.1%), a divergence that typically signals either a mean-reversion bounce candidate or the early stage of a trend reversal, and the modest +1.3% single-day gain on the latest close hints at nascent dip-buying interest. Key technical levels are well-defined: support sits at the 52-week low of $40.43, roughly 30% below the current price, while resistance is anchored at the 52-week high of $90.80, approximately 57% above. A breakout above the $65–$70 zone (where the stock consolidated in August) would signal trend repair, while a breakdown below the $55.36 August low would open the door to a retest of the $40s. With a max drawdown of -37.5% already realized and a short ratio of just 1.66 (indicating limited short-seller conviction), the setup favors patient accumulation near support rather than chasing momentum, though the absence of a beta figure in the data limits precise volatility-adjusted position sizing.
Beta
—
—
Max Drawdown
-37.5%
Largest decline past year
52-Week Range
$40-$91
Price range past year
Annual Return
—
Cumulative gain past year
| Period | SOLS Return | S&P 500 |
|---|---|---|
| 1m | -6.7% | +1.0% |
| 3m | -1.7% | +2.5% |
| 6m | -26.5% | +13.9% |
| 1y | — | +15.0% |
| ytd | +22.2% | +13.5% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
SOLS Fundamental Analysis
Solstice's revenue trajectory is solidly positive, with Q2 2026 revenue of $1.148 billion representing 11.1% year-over-year growth, accelerating from Q1 2026's $991 million and Q4 2025's $987 million. The sequential progression from $969 million in Q3 2025 to $1.148 billion in Q2 2026 reflects a clear upward trend, and the product segment dominates the mix at $1.062 billion versus $86 million in services, meaning the company's fortunes are tied to specialty chemicals volumes and pricing rather than higher-margin service revenue. The 11.1% YoY growth rate is respectable for a mature specialty chemicals business and suggests the low-GWP refrigerant transition and semiconductor materials demand are providing genuine tailwinds, though the heavy product concentration means any HVAC or auto end-market softness would hit results disproportionately. Profitability is improving meaningfully: Q2 2026 net income reached $119 million on a 10.4% net margin, up from $85 million and an 8.6% net margin in Q1 2026, and gross margin expanded to 32.2% from 31.9% sequentially. The operating margin of 18.8% and EBITDA of $279 million (24.3% EBITDA margin) in Q2 represent the strongest quarterly profitability in the trailing eight quarters, a notable achievement given the company's recent spinoff from Honeywell and the associated dis-synergies. The gross margin of 32.2% is somewhat below the 34.6% recorded in Q2 2025, suggesting some cost pressure or mix shift, but the net margin improvement from 1.5% a year ago to 10.4% now reflects dramatically better cost control and the absence of spinoff-related one-time charges. The balance sheet carries moderate leverage with a debt-to-equity ratio of 1.72 and a current ratio of 1.39, which is adequate but not fortress-like for a specialty chemicals company. Free cash flow is a bright spot: Q2 2026 FCF of $124 million on operating cash flow of $262 million and capex of $138 million, with TTM FCF of $180 million, and the company holds $750 million in cash against $12 million in quarterly dividends. The FCF yield of roughly 2.3% (on a $7.7 billion market cap) is modest, and the price-to-free-cash-flow ratio of 113x on the historical data is elevated, but the improving cash generation and 16.8% ROE suggest the company can fund its growth internally without relying heavily on external financing, though the 1.72 debt-to-equity ratio warrants monitoring.
Quarterly Revenue
$1.1B
2026-06
Revenue YoY Growth
+11.1%
YoY Comparison
Gross Margin
32.2%
Latest Quarter
Free Cash Flow
$180000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is SOLS Overvalued?
Because Solstice is profitable with positive trailing net income (EPS of $0.03 on a trailing basis, but $0.75 in the most recent quarter), the PE ratio is the appropriate primary metric, and the trailing PE of 32.6x versus a forward PE of 17.2x reveals a dramatic gap that implies the market expects earnings to roughly double over the next twelve months. This expectation is supported by the analyst consensus EPS estimate of $4.70 for the forward period, which against the current $57.70 price yields the 17.2x forward multiple, and the compression from 32.6x to 17.2x suggests the market is pricing in substantial earnings normalization as spinoff costs roll off and operating leverage kicks in. The PS ratio of 1.99x and EV/Sales of 2.62x provide a cross-check, and both are moderate for a specialty chemicals company with 32.2% gross margins and an 18.8% operating margin. Peer comparison is challenging given the limited industry average data provided, but the PS ratio of 1.99x is notably below the 7.4x–12.3x range seen in the historical ratios data from earlier periods, suggesting the stock has de-rated significantly from its post-spinoff valuation highs. The EV/EBITDA of 10.5x is reasonable for a specialty chemicals business with stable cash flows, and the PEG ratio of -0.74 (negative due to the trailing earnings base) is not meaningful, but the forward PE of 17.2x against an estimated EPS growth rate implied by the $4.70 estimate versus the trailing $0.03 suggests an extremely low PEG on a forward basis. The premium/discount assessment is complicated by the lack of a clean industry average, but the stock's PB ratio of 5.47x is elevated relative to the 2.2x–2.4x seen in early 2025, reflecting the market's willingness to pay up for the standalone company's asset base. Historical context is instructive: the PE ratio has ranged from 16.6x (Q2 2025) to 46.7x (Q4 2025) to the current 32.6x, while the PS ratio has compressed from 12.3x in Q2 2026 to 1.99x now, a massive de-rating that reflects both the earnings improvement and the stock price decline. The current PS of 1.99x is near the bottom of the historical band, which could signal either a value opportunity or a market that has permanently re-rated the stock lower post-spinoff, and the forward PE of 17.2x is at the low end of the historical range, suggesting the market is pricing in execution risk despite the strong Q2 results.
PE
32.6x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 12x~47x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
10.7x
Enterprise Value Multiple
Investment Risk Disclosure
Solstice carries moderate financial risk stemming from its 1.72 debt-to-equity ratio and $23 million in quarterly interest expense, which consumes roughly 10% of operating income. The company's heavy product concentration — $1.062 billion of $1.148 billion in Q2 2026 revenue came from products versus only $86 million from services — means any HVAC or automotive end-market softness would hit results disproportionately, and gross margin has already compressed to 32.2% from 34.6% a year ago. While free cash flow of $124 million in Q2 2026 and $750 million in cash provide adequate liquidity, the 2.3% FCF yield and 113x price-to-free-cash-flow ratio leave little margin for error if capital expenditures of $138 million per quarter rise further or if the spinoff-related dis-synergies prove more costly than anticipated.
Market and competitive risks are elevated given the stock's 31.4% underperformance versus SPY over three months and 41.8% over six months, a clear signal of institutional rotation away from the materials spinoff. The PS ratio has de-rated from 12.3x to 1.99x, and the PB ratio of 5.47x remains well above the 2.2x-2.4x range seen in early 2025, leaving room for further multiple compression if the market permanently re-rates specialty chemicals spinoffs lower. Recent news flow highlights that the automation and aerospace pieces of the Honeywell breakup are drawing more investor enthusiasm, leaving Solstice to prove its standalone earnings power without parental support, and the absence of a beta figure in the data limits precise volatility-adjusted position sizing. Regulatory tailwinds from HFC phasedowns are a double-edged sword — they support refrigerant demand but also invite competitive entry and potential policy reversals.
The worst-case scenario would involve a combination of Q3 2026 earnings miss, gross margin falling below 30%, and analyst downgrades that force a retest of the 52-week low of $40.43, representing a 30% decline from the current $57.70. If the market decides that the forward EPS estimate of $4.70 is unachievable and re-rates the stock to the trailing PE of 32.6x on lower earnings, the downside could extend toward the analyst low target of $65.00 — though that target is above the current price, suggesting analysts see limited fundamental downside. A more realistic adverse scenario would see the stock trade down to the $45-$50 range, a 13-22% decline, if revenue growth decelerates below 8% and the forward PE compresses to 12x on a $4.00 EPS estimate. The already-realized max drawdown of 37.5% demonstrates that this stock can lose more than a third of its value in a matter of months, and investors should size positions accordingly.
FAQ
The most severe risk is financial: the debt-to-equity ratio of 1.72 and $23 million in quarterly interest expense consume roughly 10% of operating income, and the heavy product concentration ($1.062 billion of $1.148 billion Q2 2026 revenue) means any HVAC or automotive end-market softness would hit results disproportionately. Second is competitive/market risk: the PS ratio has de-rated from 12.3x to 1.99x, and the stock has underperformed SPY by 41.8% over six months, suggesting institutional rotation away from materials spinoffs that could continue. Third is company-specific execution risk: the forward EPS estimate of $4.70 versus trailing EPS of $0.03 is a massive gap that must be bridged, and gross margin has already compressed to 32.2% from 34.6% a year ago. Fourth is macro/regulatory risk: the low-GWP refrigerant thesis depends on continued HFC phasedown enforcement, and any policy reversal or delay would undermine a core growth driver. Ranked by severity: financial leverage, execution risk, competitive de-rating, and regulatory dependence.
The 12-month forecast is divided into three scenarios. The base case (50% probability) targets $65.00-$79.63, assuming revenue grows 11-13% YoY, gross margin stabilizes at 32-33%, and the forward EPS of $4.70 is achieved, driving the stock toward the analyst average target. The bull case (30% probability) targets $79.63-$86.00, requiring Q3/Q4 earnings beats, revenue growth above 12%, and multiple expansion as the market gains confidence in the standalone strategy. The bear case (20% probability) targets $40.43-$65.00, driven by a Q3 earnings miss, revenue growth below 8%, gross margin below 30%, and a retest of the 52-week low. The most likely scenario is the base case, with the key assumption being that Solstice delivers on the $4.70 EPS estimate and the market gradually re-rates the stock from 17.2x forward PE toward 20x.
SOLS appears fairly valued to slightly undervalued on forward metrics but expensive on trailing and asset-based measures. The forward PE of 17.2x is at the low end of the historical range (16.6x-46.7x) and well below the trailing PE of 32.6x, while the PS ratio of 1.99x has collapsed from 12.3x in Q2 2026 and is near multi-year lows. However, the PB ratio of 5.47x remains elevated relative to the 2.2x-2.4x seen in early 2025, and the EV/EBITDA of 10.5x is reasonable but not cheap for a specialty chemicals company. The market appears to be pricing in execution risk and skepticism about the $4.70 forward EPS estimate, implying that if Solstice delivers on analyst expectations, the stock could re-rate higher toward the $79.63 average target. The valuation verdict is that the market is paying a fair price for a business with improving fundamentals but unresolved post-spinoff uncertainty.
From a risk/reward perspective, SOLS offers a compelling but not risk-free opportunity. The stock trades at $57.70 with an average analyst target of $79.63 (38.0% upside) and a strong buy consensus from 8 analysts, while the forward PE of 17.2x on an estimated $4.70 EPS is less than half the trailing PE of 32.6x. However, the stock has fallen 37.5% from its 52-week high of $90.80 and underperformed SPY by 41.8% over six months, and the trailing EPS of just $0.03 means the forward estimate is highly uncertain. The biggest downside risk is a retest of the 52-week low of $40.43, representing a 30% decline from current levels. For investors with a medium-term horizon and tolerance for volatility, the risk/reward is favorable, but position sizing should reflect the 37.5% max drawdown already realized.
SOLS is better suited for medium-to-long-term investment (minimum 12-18 months) than short-term trading, given the company's early-stage post-spinoff transition, the 37.5% max drawdown already realized, and the lack of a clear technical bottom. The stock's beta is not provided in the data, but the 41.8% underperformance versus SPY over six months and the 37.5% peak-to-trough decline indicate high volatility that makes short-term trading risky without precise volatility-adjusted position sizing. The dividend yield of 0.19% is negligible, so income is not a reason to hold. Earnings visibility is improving (Q2 2026 net income of $119 million, strongest in eight quarters) but remains uncertain given the forward EPS estimate of $4.70 versus trailing $0.03. A suggested minimum holding period of 12-18 months allows time for the spinoff transition to complete, for Q3/Q4 2026 results to validate the earnings trajectory, and for the market to potentially re-rate the stock toward analyst targets.
